Search 

The company was founded in 2016 by Dr Mark Kotter from his labs at the University of Cambridge. It has raised over $150m in funding so far, has over 180 employees and is headquartered in Cambridge, UK and San Francisco, US. bit.bio combines the concepts of cellular reprogramming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines.

This is possible with our precision cellular reprogramming technology, opti-ox™ - a core component of our Cell Identity Coding Platform. opti-ox is a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through rapid reprogramming of stem cells. ioCells™
Under our ioCells brand we have a wide range of wild type and disease model cells available for research and drug discovery including human iPSC-derived nerve, immune and muscle cells. Our portfolio is expanding at pace and all our cells are powered by opti-ox so are consistent, easy to use and highly defined. Cell therapy
We are currently building a clinical pipeline of cell therapies. Our areas of development are liver, immune and metabolic.

PrecisionLife is an innovative techbio changing the way the world looks at predicting, preventing, and treating chronic diseases - extending the reach of precision medicine beyond cancer and rare disease for conditions that account for over 80% of healthcare spending. We stratify patient populations at an unprecedented level of resolution to reveal the deepest disease insights in complex, chronic conditions. Our scalable platform is generating a growing IP portfolio of novel drug targets, drug response biomarkers, and precision repositioning assets for over 45 indications. All our assets are protected by our unique and highly specific patient stratification biomarkers, with an understanding of disease prevalence, efficacy and secondary indication potential to maximize their probability of success in clinical development. Our unparalleled understanding of disease biology and patient stratification informs and derisks every stage of drug discovery and development, giving major competitive advantages and creating additional revenue opportunities for our biopharma partners. Recent deals offer significant commercial validation to our approach:

• Multi-target R&D Partnership: Strategic R&D partnership with Ono Pharmaceutical to discover and validate multiple novel therapeutic targets in CNS, signed in Dec'22
• Precision Neuroscience Partnership: Collaboration with Sosei Heptares for deeper evaluation of one of their GPCR targets, signed in Nov'22

At Bio-Europe, we are prioritizing meetings with companies interested in partnering around a range of complex chronic disorders, including CNS, respiratory, immunological and cardiometabolic indications, and those seeking partnerships around novel targets, precision drug repositioning, clinical trial analysis and patient stratification biomarkers in complex chronic disorders.